Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, Jul 6 () Drug firm Zydus Cadila on Monday said it has received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidate Desidustat in the management of COVID-19. "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico," Cadila Healthcare said in a regulatory filing. The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients. "As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial," the company added. Zydus Cadila Chairman Pankaj R Patel said, "At Zydus, we have been stepping up our efforts to fight the COVID-19 pandemic through therapeutic drugs, diagnostics and vaccines. With Desidustat we will study a novel approach for management of COVID-19". Zydus had initiated two phase-III trials of Desidustat. Last week, Zydus had received approval from Indian authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide. Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 363.40 apiece on BSE, 0.78 per cent lower against their previous close. SVK ANS ANS

Zydus Cadila gets approval from Mexican authority to test COVID-19 drug

New Delhi, Jul 15 () Drug firm Zydus Cadila on Wednesday said it has received final nod from the US health regulator to market generic Betamethasone Dipropionate ointment used for the treatment of a variety of skin conditions. The company has received final approval from the United States Food and Drug Administration (USFDA) to market Betamethasone Dipropionate ointment USP 0.05 per cent, Zydus Cadila said in a statement. The ointment will be manufactured at the group's topical manufacturing facility at Ahmedabad, in Gujarat, it added. The product is used to treat a variety of skin conditions such as, eczema, dermatitis, allergies and rashes, Zydus Cadila said. The group now has 293 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added. Shares of Cadila Healthcare, the listed entity of the Zydus Group, were trading at Rs 356.50 per scrip on BSE, up 0.81 per cent from its previous close. AKT DRR DRR

Zydus Cadila gets USFDA nod to market ointment for treating skin conditions

New Delhi, Dec 11 () Drug firm Zydus Cadila on Wednesday said it has launched its affordable oral anti-diabetic Vinglyn brand tablets available in two formulations in India.
 As the product patent on popular diabetes drug Vildagliptin has expired in India on December 9, some domestic drug firms have launched the generic versions of the drug in the country that are much cheaper than the patented medicine.
 "Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India," Zydus Cadila said in a statement.
 Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd, it added.
 Zydus Cadila Managing Director Sharvil Patel said, "Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society."
 With Vinglyn, Zydus Cadila believes that it has once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from type-2 diabetes, in India, he added.
 With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.
 The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management, the statement said.
 Another drug firm Panacea Biotec on Tuesday had said it had launched its VilACT brand tablets available in four formulations, for treatment of type-2 diabetes in India.
 The company had also said its brand will be an affordable and high-quality medicine.
 According to the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs 969 crore and is growing at the rate of 4 per cent, Panacea Biotec had said.
 Shares of Cadila Healthcare, the listed entity of the Zydus group closed at Rs 262.25 per scrip on the BSE, up 0.50 per cent from its previous close. AKT HRS

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

New Delhi, Mar 11 () Drug firm Cadila Healthcare on Wednesday said its board has approved the transfer of its animal healthcare business on a going concern basis to its wholly-owned arm Zydus Animal Health and Investments Ltd (ZAHL) as part of its internal restructuring exercise. The transfer of animal healthcare business is through execution of a definitive agreement, Cadila Healthcare said in a filing to BSE. The animal healthcare business (AHB) consists of development, manufacturing, marketing and selling of animal healthcare products in India and other countries, it added. "No cash consideration will be paid by ZAHL for transfer of AHB. ZAHL will issue and allot 227,33,50,000, 8 per cent non-convertible non-cumulative redeemable preference shares of Rs 10 each at face value, aggregating to Rs 2,273.35 crore, in exchange for transfer of AHB," Cadila Healthcare said. ZAHL is engaged in the business of pharmaceuticals and investments, it added. Cadila Healthcare Ltd and ZAHL are the parties to the definitive agreement, the filing said. Cadila Healthcare shares closed at Rs 258.15 on BSE, up 0.84 per cent from the previous close. AKT MR

Cadila Healthcare board approves transfer of animal healthcare biz to subsidiary

New Delhi, Feb 13 () Zydus Cadila on Thursday said it has got final approval from the US health regulator to market Mesalamine suppositories. The drug is used to treat ulcerative proctitis, a type of bowel disease. "Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg," the drug firm said in a regulatory filing. Mesalamine Suppositories is an aminosalicylate anti-inflammatory drug and is believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group's topical manufacturing facility at Ahmedabad. The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. Shares of Cadila Healthcare, the listed entity of the group, were trading down 0.10 per cent at Rs 1,468.95 per scrip on BSE. SID DRR

Zydus Cadila gets USFDA nod to market Mesalamine suppositories

New Delhi, May 21 () Drug firm Cadila Healthcare on Thursday said the first batch of 30,000 COVID Kavach Elisa tests manufactured by its arm Zydus Diagnostics have been supplied to Indian Council of Medical Research (ICMR), free of cost. These test kits have been manufactured in technology transfer with ICMR-NIV of Pune for surveillance purposes, Cadila Healthcare said in a filing to BSE. Earlier, the company had partnered with ICMR to be better equipped against infectious disease outbreaks, and help people, who are at high risk, particularly in distant, remote areas of the country, the filing said. The company has been manufacturing and marketing a range of Elisa kits for detection and surveillance of rare and neglected diseases in humans and livestock, it added. Shares of Cadila Healthcare were trading at Rs 344 per scrip on BSE, up 1.91 per cent from its previous close. AKT MR MR

Zydus Cadila supplies 30,000 COVID Kavach Elisa test kits to ICMR for free

(Eds: Adds details) New Delhi, Mar 5 () Zydus Cadila has received approval from the Drug Controller General of India (DCGI) for its new drug application for Saroglitazar to treat a particular condition of liver, commonly known as NASH in India, the drug major said on Thursday. The Ahmedabad-based company said the approved product is the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) which is a progressive disease of the liver. The condition starts with fat accumulation in the liver known as non-alcoholic fatty liver disease and progress to cirrhosis and liver failure. Commenting on the approval, Zydus Group Chairman Pankaj Patel said, "We are happy that our efforts to discover and develop a novel drug for patients living with NASH, an unmet healthcare need globally, have been successful. Saroglitazar will provide hope and new lease of life for millions of patients in India suffering from NASH". The company had launched Saroglitazar in India in September 2013 for treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with Type-2 diabetes not controlled by statins alone. In January this year, Saroglitazar received an approval for the treatment of Type-2 diabetes Mellitus. In the last seven years, over a million patients have benefitted from this drug, Zydua Cadila said. The drug has been found to reduce significantly liver fat, liver enzymes and disease activity during trials in India, the company said, adding it has also met primary and secondary endpoints during trials in the US. NASH is a large unmet medical need as there is currently no approved drug for the treatment anywhere in the world, a disease that is highly prevalent with 10 per cent to 30 per cent of the global population being affected by it. The prevalence of NASH in India is estimated to be nearly 25 per cent of the population. NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure. Shares of Cadila Healthcare, a listed entity of the Zydus group, ended 3.67 per cent up at Rs 265.40 apiece on the BSE. MSS MRMR

Zydus Cadila gets DCGI nod for world's first drug to treat liver disease

New Delhi, Nov 21 () Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest pain.
 The drug firm has also received final approval from US health regulator for Desonide Cream, used to treat a variety of skin conditions like eczema, dermatitis, allergies and rash, the company said in a filing to BSE.
 "Zydus Cadila has received the final approval from the USFDA to market Isosorbide Dinitrate tablets USP...in the strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg," the filing said.
 The drug is used to prevent attacks of chest pain. lt dilates blood vessels, making it easier for blood to flow through them and easier for the heart to pump.
 It will be manufactured at the Group's formulations manufacturing facility at Baddi, Himachal Pradesh.
 "The group also received the final approval for Desonide Cream (US RLD - Desonide Cream), 0.05 per cent," the filing said.
 The drug is a mild corticosteroid, used to treat a variety of skin conditions like eczema, dermatitis, allergies and rash, to reduce swelling, itching and redness that can occur in these types of conditions.
 It will be manufactured at the Group's topical manufacturing facility at Ahmedabad, it said.
 The shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 251.35, higher by 0.92 per cent on the BSE. SID DRR

Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream

New Delhi, Mar 30 () Domestic pharma major Zydus Cadila, part of Cadila Healthcare group, on Monday said it has received tentative approval from the US health regulator for its generic version of Parkinson's disease treatment drug Carbidopa and Levodopa extended-release capsules. The approval by the US Food and Drug Administration is for Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Cadila Healthcare said in a regulatory filing. This combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms such as shakiness, stiffness, and difficulty moving and will be manufactured at the group's manufacturing facility at special economic zone (SEZ), Ahmedabad, it added. The group now has 282 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it said. RKL RKL ANSANS

Zydus Cadila gets tentative nod from USFDA for Parkinson's treatment capsule

New Delhi, Mar 5 () Pharmaceutical major Zydus Cadila on Thurday said it has received Drug Controller General of India (DCGI) approval for its new drug application for Saroglitazar to treat a particular condition of liver, commonly known as NASH in India.Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) is a progressive disease of the liver, which starts with fat accumulation in the liver known as non-alcoholic fatty liver disease. This condition could progress to cirrhosis and liver failure, the company said in a statement.Commenting on the approval, Zydus Group Chairman Pankaj Patel said, "We are happy that our efforts to discover and develop a novel drug for patients living with NASH, an unmet healthcare need globally, have been successful. Saroglitazar will provide hope and new lease of life for millions of patients in India suffering from NASH".The company had launched Saroglitazar in India in September 2013 for treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with Type-2 diabetes not controlled by statins alone.In January this year, Saroglitazar received an approval for the treatment of Type-2 diabetes Mellitus. In the last seven years, over a million patients have benefitted from this drug, Zydua Cadila said.The drug has been found to reduce significantly liver fat, liver enzymes and disease activity during trials in India, the company said, adding it has also met primary and secondary endpoints during trials in the US. RKL BAL

Zydus Cadila gets DCGI nod for Saroglitazar to treat liver disease

New Delhi, Jul 3 () Zydus, a part of the Cadila Healthcare group, on Friday said its indigenously developed COVID-19 vaccine candidate - ZyCoV-D - has successfully completed pre-clinical phase and has received permission from Indian authorities to conduct human trials. "Zydus has already manufactured clinical good manufacturing practice (GMP) batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1,000 subjects," the company said. ZyCoV-D, developed at the company's Vaccine Technology Centre in Ahmedabad, has now received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organisation (CDSCO) to initiate phase I/II human clinical trials in India, Cadila Healthcare said in a regulatory filing. In animal studies the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate, it said. It further said no safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic. Zydus said, with its ZyCoV-D, it has successfully established the DNA vaccine platform in India using non-replicating and non-integrating plasmid carrying the gene of interest making it very safe. The company claimed that the vaccine candidate has no vector response and with absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements. It is also known to show much improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest parts of the country, it said. "Furthermore, the platform can be rapidly used to modify the vaccine in couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection," it added. The company now intends to rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand. RKL ANS ANS

Zydus says potential COVID-19 vaccine gets DGCI nod for human trials

(Eds: Adds details about COVID vaccine) New Delhi, Jul 3 () Zydus on Friday said it has received approval from authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide. The vaccine, ZyCoV-D, showed a "strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus, part of Cadila Healthcare Ltd, said in a statement. This comes within days of Bharat Biotech's Covaxin vaccine getting approval of the drug regulator to start clinical trials. Over seven vaccines are being researched in India and two of them have got go-ahead to start human clinical trials just this week. Globally, over 100 candidates are being tested on humans but no vaccine has yet been approved. "Zydus has already manufactured clinical good manufacturing practice (GMP) batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1,000 subjects," the company said. ZyCoV-D, developed at the company's Vaccine Technology Centre in Ahmedabad, has now received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organisation (CDSCO) to initiate phase I/II human clinical trials in India, Cadila Healthcare said. In animal studies, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate, it said. It further said no safety concerns were observed for the vaccine candidate in repeat-dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well-tolerated and immunogenic. Zydus said, with its ZyCoV-D, it has successfully established the DNA vaccine platform in India using non-replicating and a non-integrating plasmid carrying the gene of interest making it very safe. The company claimed that the vaccine candidate has no vector response and with the absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements. It is also known to show much-improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest parts of the country, it said. "Furthermore, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection," it added. The company now intends to rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand. RKL MR

Zydus gets nod for human trials of COVID-19 vaccine

Drug maker <keyword id="63358" type="PERSON" weightage="20" keywordseo="Cadila-Healthcare">Cadila Healthcare</keyword> Limited has clarified that its drugs in the US have been recalled by its US subsidiary, Zydus Pharma USA; it was a class III type recall. The company gave the clarification following a news report that stated that the company had to recall one of its drugs in the US market. 
	 "The recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health co<keyword id="6354646" type="CITY" weightage="20" keywordseo="NSE">nse</keyword>quences. There is no material impact”, said the company in a letter to the National Stock Exchange (NSE). 
	 The NSE on December 31, 2014, had sought clarification from the pharma major after a news report suggested that along with Wockhardt and Hospira, Cadila too has voluntarily recalled 58,920 bottles of Benzonatate Capsules—these medicines are used to treat coughs. The US Food and Drug Administration (<keyword id="6354656" type="ORGANIZATION" weightage="20" keywordseo="FDA">FDA</keyword>) had published this information on its website. 
	 
	Representational Image

Cadila Clarifies Voluntary Recall Of Drugs In
The US Market

<ul><li>In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing. </li><li>The adaptive phase I/ II <keyword id="977427" type="PERSON" weightage="20" keywordseo="human-clinical-trials">human clinical trials</keyword> of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine." </li><li>Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> infections worldwide. </li></ul><keyword id="9577763" type="UNKNOWN" weightage="20" keywordseo="drug-firm-zydus-cadila">Drug firm Zydus Cadila</keyword> on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing. The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine." Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide. It got approval a few days after India's first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> in collaboration with <keyword id="6364555" type="COMPANY" weightage="20" keywordseo="Indian-Council-of-Medical-Research">Indian Council of Medical Research</keyword> and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 356.50 apiece on BSE, up 0.81 per cent against their previous close. SEE ALSO: <a href="https://www.businessinsider.in/india/news/photographer-of-the-viral-black-panther-images-from-india-shares-his-story/articleshow/76830618.cms">INTERVIEW: Shaaz Jung opens up about the blood, sweat and years behind the viral images of a rare black panther</a> <a href="https://www.businessinsider.in/tech/news/intel-will-speed-up-mukesh-ambanis-5g-run-power-him-with-ai-and-possibly-a-jio-laptop/articleshow/76780290.cms">Intel will speed up Mukesh Ambani’s 5G run, power him with AI and possibly a Jio laptop⁠— all in return for massive amount of data</a>

Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate

Drug maker Cipla Limited on Sunday announced the launch of experimental anti-viral drug remdesivir under its <keyword id="9441113" type="UNKNOWN" weightage="20" keywordseo="brand-name-cipremi">brand name Cipremi</keyword>. Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, US drug maker Gilead Sciences extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remedisvir called Cipremi. The Drug Controller General of India (DCGI) has granted Cipla regulatory approval for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said in a statement. As part of a risk management plan, Cipla will provide training on use of the drug, inform patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> on Indian patients. "Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by Covid-19 pandemic, and this launch is a significant milestone in that direction," said Umang Vohra MD and Global CEO, Cipla. According to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study, a randomized clinical trial conducted with remdesivir on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator. The mortality rates in the study were 7.1 per cent in those given remdesivir and 11.9 per cent in those who were given placebo. In May, Gilead Sciences signed non-exclusive voluntary licensing agreements with six Indian pharmaceutical companies to boost the supply of remdesivir, the experimental antiviral drug that has shown promise in Covid-19 treatment. These companies were -- Dr. Reddy's Laboratories Ltd., <keyword id="9441116" type="COMPANY" weightage="20" keywordseo="zydus-cadila-healthcare-ltd-">Zydus Cadila Healthcare Ltd.</keyword>, Biocon company Syngene, Hetero Labs Ltd.; Jubilant Lifesciences; and Cipla Ltd. Media reports said that Hetero Labs Ltd has also received regulatory approval from DCGI but the drug maker was yet to make it official. Cipla said it will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through government and open market channels, to ensure equitable distribution. SEE ALSO: <a href="https://www.businessinsider.in/india/news/water-sold-in-aluminum-cans-to-avoid-plastic-use-is-the-latest-trend-in-india/articleshow/76490551.cms" data-type="tilCustomLink">Water sold in aluminum cans to avoid plastic use is the latest trend in India – but costs six times than that of a mineral water bottle</a> <a href="https://www.businessinsider.in/tech/news/can-non-chinese-mobile-brands-leverage-current-consumer-sentiment-in-india/articleshow/76490835.cms" data-type="tilCustomLink">Can non-Chinese mobile brands leverage current consumer sentiment in India?</a>

You Searched For "zydus cadila healthcare ltd" and got 15 results

Zydus Cadila gets approval from Mexican authority to test COVID-19 drug

PTI

Zydus Cadila gets USFDA nod to market ointment for treating skin conditions

PTI

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

PTI

Cadila Healthcare board approves transfer of animal healthcare biz to subsidiary

PTI

Zydus Cadila gets USFDA nod to market Mesalamine suppositories

PTI

Zydus Cadila supplies 30,000 COVID Kavach Elisa test kits to ICMR for free

PTI

Zydus Cadila gets DCGI nod for world's first drug to treat liver disease

PTI

Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream

PTI

Zydus Cadila gets tentative nod from USFDA for Parkinson's treatment capsule

PTI

Zydus Cadila gets DCGI nod for Saroglitazar to treat liver disease

PTI

Zydus says potential COVID-19 vaccine gets DGCI nod for human trials

PTI

Zydus gets nod for human trials of COVID-19 vaccine

PTI

Cadila Clarifies Voluntary Recall Of Drugs In The US Market

Purba Das

Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate

PTI

Cipla to sell anti-viral drug remdesivir as Cipremi in India

IANS

Popular Keywords

Buying Guides